Cambridge, Mass. – September 30, 2026 -- Insilico Medicine (HKEX: 3696) has nominated ISM1354, an AI-designed small molecule GIPR antagonist, as a preclinical candidate for obesity, type 2 diabetes and potential cardiovascular applications tied to obesity-associated heart failure.

Las Vegas – – September 15, 2026 -- The obesity therapeutics market across the seven major markets was valued at approximately USD 16 billion in 2025 and is projected to grow at a 27% CAGR through 2036, according to DelveInsight, as a wave of next-generation candidates threatens to disrupt the Eli Lilly-Novo Nordisk duopoly.

Houston – September 15, 2026 -- Fiber broadband has added an estimated $1.6 billion in aggregate home value to single-family homes sold across Houston since 2020, according to an independent study commissioned by Ezee Fiber titled "Fueling Houston's Growth with Fiber."

Wellesley Hills, Mass. – – September 13, 2026 -- Cure Alzheimer's Fund (CureAlz) has appointed Drs. Michelle Arkin, Ronald B. DeMattos, Donna M. Huryn, and Kalpana Merchant to its Scientific Advisory Board (SAB), adding decades of pharmaceutical drug-discovery experience to the nonprofit's research-funding strategy.

Cambridge, Massachusetts – September 09, 2026 -- Insilico Medicine has published data in Nature Biotechnology showing that its AI-designed idiopathic pulmonary fibrosis (IPF) candidate rentosertib reversed predicted biological age by up to six years in some patients, based on six independently developed proteomic aging clocks.